

Advances in Neuroblastoma Research Meeting (ANR 2025)

May 25 - 28, 2025

SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions | |
|----------------------|---|--|---|--------------------------|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions | |
| | Other Sessions | Sponsored Symposia | Social Events | |
| Sunday, May 25, 2025 | | | | |
| Time Slot | Hall A (Potomac Room 1) | Hall B (Potomac Room 2) | Hall C (Meeting Room 16) | Meeting Room 12/13/14 |
| 08:30 - 08:45 | ANR 2025 Meeting Opening & Welcome | | | |
| 08:45 - 09:45 | <p>Plenary Session 1: New T-cells and Targets <i>Chairs: Robbie Majzner, Kelly Goldsmith</i></p> <p>PHOX2B-directed peptide-centric CAR (PC-CAR) T cells show specificity and potent efficacy in preclinical models of high-risk neuroblastoma, Muzamil Y Want, US</p> <p>Targeting gangliosides in pediatric cancer, Guillermo N Dalton, US</p> <p>Safety and efficacy in a first-in-human GPC2 chimeric antigen receptor (CAR) T cell phase 1 trial for neuroblastoma, Kristopher R. Bosse, US</p> <p>Prevention of metastatic neuroblastoma using gene therapy to persistently express bispecific T-cell engaging diabodies, Timothy P. Cripe, US</p> | | <p>09:20 - 10:30 Nursing Symposium</p> <p>09:20 – 09:30 Welcome/Housekeeping, Jennifer Saggio & Jessica Stafford</p> <p>09:30 – 10:00 High-risk neuroblastoma overview, Linda D’Andrea</p> <p>10:00 - 10:30</p> <p>Current and upcoming studies in The Children’s Oncology Group for patients with neuroblastoma, Wendy Fitzgerald</p> <p>Current and upcoming studies in the new approaches to neuroblastoma therapy consortium, Jennifer Saggio</p> | |
| 09:45 - 10:30 | <p>Keynote Lecture 1 <i>Chair: John Maris</i></p> <p>Nucleoside-modified mRNA-LNP therapeutics</p> <p>Drew Weissman, US</p> | | | |
| 10:30 - 11:00 | Coffee Break | | | |
| 11:00 - 11:50 | <p>Parallel Session 1: Novel Targets and Therapies (Transl) <i>Chairs: Jennifer Foster, Jayne Murray</i></p> <p>Ex vivo drug sensitivity profiling to complement molecular profiling in precision medicine for pediatric Neuroblastoma and other solid tumors, Marlinde Celine Schoonbeek, Netherlands</p> <p>Targeting lineage heterogeneity in neuroblastoma via cGAS-STING, Adam J Wolpaw, US</p> <p>Identification of canonical and non-canonical immunotherapeutic targets to overcome therapy-resistance in neuroblastoma, Damon Hofman, Netherlands</p> <p>ALCAM is a neuroblastoma oncoprotein and immunotherapeutic target, Jarrett Lindsay, US</p> <p>Prodrug-based therapy targeted to the norepinephrine transporter shrinks tumors and extends survival in models of recurrent ATRX-mutant neuroblastoma, Michael Chorny, US</p> | <p>Parallel Session 2: Optimizing GD2 therapies (Clin) <i>Chairs: Sara Federico, Judith Wienke</i></p> <p>Real-world data from SACHA-France on chemo-immunotherapy for relapsed high-risk neuroblastoma: predictive factors for outcome, Claudia Pasqualini, France</p> <p>Efficacy and tolerability of</p> <p>Topotecan/Cyclophosphamide/Dinutuximab/GM-CSF in relapsed and refractory high-risk neuroblastoma, Benjamin J. Lerman, US</p> <p>Five-Year Outcome of High-risk Risk Neuroblastoma Patients Treated on NB2012, A Phase 2 Chemoimmunotherapy Induction Regimen with Hu14.18K322A, Megan M Lilley, US</p> <p>Respiratory failure during concomitant Lorlatinib, Sargramostim, and Dinutuximab Administration: Children’s Oncology Group (COG) ANBL1531 Experience, Emily Greengard, US</p> <p>Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma efficacy of GD2-directed immunotherapy with dinutuximab beta, Holger N. Lode, Germany</p> | <p>11:00 - 11:40 Nursing Symposium (continue)</p> <p>11:00- 11:40 Circulating tumor DNA (ctDNA) and it’s use in Neuroblastoma therapy, Jennifer Saggio</p> | |

Advances in Neuroblastoma Research Meeting (ANR 2025)

May 25 - 28, 2025

SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|---|---------------------|---|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 11:50 - 14:10 | Lunch Break & Poster Viewing Group A | | 11:40 – 12:00 Nursing break/grab lunch and rejoin symposium |
| | 12:20 - 13:05 Patient & Parent Perspectives on High-Risk Neuroblastoma Moderator: Lisa Diller An inspiring panel to share insights from across the treatment, survivorship and bereavement spectrum. | | 12:00 - 16:00 Nursing Symposium (continue) 12:00 – 13:00 Anti GD2 Antibody treatment panel Dinutuximab therapy, Kristen Dalton Naxitimab therapy, Linda D’Andrea 13:00 – 13:30 I-131 MIBG therapy for patients with neuroblastoma, Jennifer Spidle 13:30 - 14:00 Survivorship issues post neuroblastoma therapy, Katie Reid 14:00 – 14:10 Comfort break 14:10 – 14:40 CART therapy for neuroblastoma, Wendy Fitzgerald 14:40 - 15:40 Parent panel: Parents will describe their journey through neuroblastoma therapy and share those concepts they believe all healthcare team members should know, Lindsay Jackson & Sara Stump 15:40 - 16:00 Wrap-up |
| | | | |
| | 13:15 - 14:00 Recordati Rare Diseases Sponsored Symposium | | |
| | | | |
| | | | |
| 14:10 - 15:10 | Plenary Session 2: Spatial, the Final Frontier Chairs: Matthias Fischer, Rosandra Kaplan Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring, Wenbao Yu, US Proteomics of the neuroblastoma secretome reveals immunosuppressive factors inhibiting T cell responses, Judith Wienke, Netherlands Deciphering the neuroblastoma tumor microenvironment using spatial omics, Noah Bonine, Belgium Evolutionary trajectories of neuroblastoma pathogenesis, Carolina Rosswog, Germany | | |
| 15:10 - 15:25 | Rapid Fire Session 1 Chair: Jan Molenaar Imaging mass cytometry reveals the spatial network of immune cells in neuroblastoma, Francisca Bergsma, Netherlands Charting adrenergic and mesenchymal interconversion through in vivo single-cell barcoding RNA sequencing in neuroblastoma, Stefano Di Giulio, US Reconstructing evolution of high-risk neuroblastoma from single-nuclei DNA sequencing data, Magdalena Seiffert, Germany Survival of relapsed/refractory neuroblastoma patients treated with dinutuximab beta long term infusion depends on FC gamma receptor and NK cells, Holger N Lode, Germany Neuroblastoma in older children, adolescents and young adults: An updated report from the International Neuroblastoma Risk Group (INRG), Rebecca J. Deyell, Canada KIR ligand mismatched allogeneic cord blood transplantation reduces bone marrow relapse in high-risk neuroblastoma stage M, Shinsuke Kataoka, Japan Phase 1 Trial of universal donor NK cell infusions with temozolomide, irinotecan, and dinutuximab in patients with relapsed/refractory neuroblastoma, Keri A Streby, US A syngeneic MYCN-driven murine neuroblastoma allograft model for TCR mimetic CAR T cell preclinical therapeutics, Elisabeth Posthill, US An immunocompetent human B7H3 neuroblastoma mouse model for preclinical development of immunotherapies, Thomas J Jackson, UK A novel MYCN-driven mouse model to allow lineage tracing of neuroblastoma cells, Lisa Werr, Germany | | |
| 15:25 - 15:55 | Coffee Break | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)
May 25 - 28, 2025
SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|--|---|--------------------|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 15:55 - 16:45 | Parallel Session 3: Landscapes and Profiles (Transl) <i>Chairs: Gudrun Schleiermacher, Esther Berko</i> The genomic landscape of relapsed neuroblastoma – What comes next? Pascal Kohmann, Germany Drug sensitivity profiling in the pediatric precision oncology program INFORM, Ina Oehme, Germany Single-cell study of bone marrow metastases reveals heterogeneity with paired primary tumor and subpopulations with therapy-resistant characteristics, Ilse Timmerman, Netherlands Spatial profiling of tumor cell states and their interaction with immune cells in high-risk neuroblastoma, Viktoria Humhal, Austria Genomic profiling in low and intermediate-risk neuroblastoma to refine treatment stratification and improve patient outcome. LINES: a SIOPEN trial, Irene Jiménez, Spain | Parallel Session 4: More Immunotherapy (Transl) <i>Chairs: Shahab Asgharzadeh, Hong Ha Rosa Nguyen</i> Adrenergic/Mesenchymal plasticity drives STING suppression and immune escape in neuroblastoma, Stefano Di Giulio, US The NK cell ligand MICA represents a lineage-specific immunogenic vulnerability in neuroblastoma, Satyaki Sengupta, US Anti-tumor efficacy of allogeneic O-Acetyl GD2-CAR NK cells against neuroblastoma, Alice L Yu, US Secreted T cell engagers directed against PTK7 enhance the potency of allogeneic $\gamma\delta$ T cell therapy for neuroblastoma, Hunter C. Jonus, US Combining CD47 blockade with chemoimmunotherapy in preclinical chemoresistant neuroblastoma models, Courtney Himsworth, UK | |
| 16:45 - 18:15 | Poster Session Group A | | |
| 18:15 - 19:45 | Welcome Reception | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)

May 25 - 28, 2025

SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|----------------------|--|--|---|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| Monday, May 26, 2025 | | | |
| Time Slot | Hall A (Potomac Room 1) | Hall B (Potomac Room 2) | Hall C (Meeting Room 16) |
| 08:00 - 08:45 | Education Session 1: Neuroblastoma Sara Federico | | US Worldmeds Sponsored Symposium |
| 08:45 - 09:00 | Comfort Break | | |
| 09:00 - 10:00 | Plenary Session 3: Circulating Tumor Material Chairs: Lieve Tytgat, Sabine Taschner-Mandl Investigation of tumor evolution mechanisms in high-risk neuroblastoma patients using liquid biopsy: A report from the children's oncology group, Gabriela Virdzekova, US Sequential cell free DNA analysis reveals genetic heterogeneity in patients with relapsed neuroblastoma enrolled in the SIOPEN-ITCC BEACON study, Gudrun Schleiermacher, France Multi-Omics profiling of neuroblastoma identifies immunological biomarkers associated with higher risk of relapse: results from the MICCHADO study, Antonio Colaprico, France Immune evasion and therapy resistance in neuroblastoma bone marrow metastasis, Sara Wernig Zorc, Austria | | |
| 10:00 - 10:45 | Keynote Lecture 2 Chair: Rochelle Bagatell Poverty as a "Druggable" Target: A framework for oncology health equity research Kira Bona, US | | |
| 10:45 - 11:15 | Coffee Break | | |
| 11:15 - 12:05 | Parallel Session 5: TERT and All That Ends Well (Basic) Chairs: Patrick Reynolds, Anneleen Decock Characterising the spatial landscape of neuroblastoma using spatially resolved transcriptomics, Pravin Velmurugan, Germany NK cells mediate tumor immune evasion in bone marrow metastasis via the ALCAM-CD6 axis in ATRX-mutated neuroblastoma, Magdalena Rados, Austria Targetable genetic alterations in high-risk neuroblastoma patients enrolled in the SIOPEN HR-NBL1 study, Angela Bellini, France Telomere maintenance mechanism and its associated genetic abnormalities in 321 neuroblastic tumors (A report from JCCG-JNBSG), Miki Ohira, Japan Clinical significance of TERT promoter mutations in neuroblastoma, Shakeel Modak, US | Parallel Session 6: More Circulating Tumor Material (Transl/Clin) Chairs: Meredith Irwin, Carolina Rosswog Development of a neuroblastoma-specific clinically validated circulating tumor DNA assay, Grace Polkosnik, US The LIQUIDHOPE consortium (ERA-NET, TRANSCAN-2): Advancing liquid biopsies for monitoring and personalized treatment of children with neuroblastoma, Marco Lodrini, Germany Serially quantifying TERT rearrangement breakpoints in cfDNA enables minimal residual disease monitoring in patients with neuroblastoma, Jan Fredrik Hollander, Germany Nucleosome footprinting enables inference of expression profiles in circulating tumor DNA from neuroblastoma patients, Gudrun Schleiermacher, France The potential of liquid biopsies by neuroblastoma-specific adrenergic and mesenchymal mRNA panels and cell-free DNA detection, Godelieve Andrea Tytgat, Netherlands | Parallel Session 7: Localized and Low Risk (Clin) Chairs: Holly Meany, Erin Brown Clinical outcome of patients with opsoclonus-myoclonus-ataxia syndrome (OMAS) treated in the SIOPEN OMS/DES2011 study, Benoit Dumont, France Reduction of treatment burden in Low-Risk Neuroblastoma with favourable biology: Results of the SIOPEN LINES trial, Vanessa Segura, Spain SIOPEN LINES trial for patients with unresectable localized, MYCN non-amplified neuroblastoma over 18 months: are really all at intermediate risk? Adela Cañete, Spain Outcomes for patients with low stage MYCN amplified neuroblastoma (INSS stage 1, 2): A report from the International Neuroblastoma Risk Group (INRG), Anne L Ryan, Australia Influence of mIBG positive Residues after Surgery on Survival in Patients with MYCN amplified localized Neuroblastoma: the HR-NBL1/SIOPEN study, Ruth Ladenstein, Austria |

Advances in Neuroblastoma Research Meeting (ANR 2025)
May 25 - 28, 2025
SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|--|---------------------|---|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 12:05 - 14:05 | Lunch Break & Poster Viewing Group B | | 12:15 - 14:00 ANR Advisory Board Meeting |
| 14:05 - 15:05 | Plenary Session 4: Optimizing Clinical Care <i>Chairs: Julie Park, Toby Trahair</i> Clinicobiological treatment stratification leads to excellent prognosis in MYCN-NA disseminated NB patients ≤12 months. Results of SIOPEN-LINES trial, Irene Jiménez, Spain Long term infusion of dinutuximab beta is associated with a survival advantage over short term infusion. Results from the HR-NBL1/SIOPEN trial, Holger N Lode, Germany Complete primary tumor resection is associated with improved outcomes in patients with high-risk neuroblastoma treated on COG ANBL0532, Christa N Grant, US Elucidating the B cell mediated anti-tumor immune response in neuroblastoma with opsoclonus myoclonus ataxia syndrome, Matthias Fischer, Germany | | |
| 15:05 - 15:20 | Rapid Fire Session 2 <i>Chair: Jo Vandesompele</i> MYCN overexpression biases human sympatho-adrenergic development towards progenitor cells causing neuroblastoma-like tumor xenografts, Stéphane Van Haver, US Proteomic insights into extracellular vesicles in neuroblastoma biology, Martin Auber, Germany Mechanisms of extracellular vesicles-mediated neuroblastoma metastasis, Vladimir S. Spiegelman, US Administration of intracerebroventricular dinutuximab in the treatment of CNS neuroblastoma and determination of CSF pharmacokinetics, Michael Migotsky, US Survival outcomes in patients with high-risk neuroblastoma on eflornithine (DFMO) maintenance: Matched external control analysis at 7-year follow-up, William Ferguson, US Inferring the evolution of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing, Christoph Bartenhagen, Germany Dinutuximab administration during Induction does not increase the development of HACA during Post-Consolidation, a report from COG ANBL17P1, Ankita Shahi, US Potential therapeutic targets for ATRX-aberrant neuroblastoma revealed by genome-wide CRISPR-Cas9 synthetic lethality screens, Fenja L. Fahrig, Netherlands Functional profiling on ex vivo neuroblastoma models: global collaboration to drive implementation in precision medicine, Eleonora Jacoba Looze, Netherlands Optimized syngeneic neuroblastoma models to advance cell therapies, Ying Wang, US | | |
| 15:20 - 15:50 | Coffee Break | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)
May 25 - 28, 2025
SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|---|--|---|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 15:50 - 16:40 | Parallel Session 8: Even More Immunotherapy (Transl) <i>Chairs: John Anderson, Annette Kuenkele</i> Identification of GDNF family receptor alpha 2 (GFRA2) as an immunotherapy target for neuroblastoma central nervous system (CNS) metastases, Benjamin Lowry, US GFRA2 as a candidate immunotherapeutic target in neuroblastoma and Ewing Sarcoma, Amber K Hamilton, US Preclinical Development of Chimeric TGFB Switch Receptor (CTSR)-Armored B7H3 CAR-T Cells for Neuroblastoma, Babak Moghimi, US VLA-4 targeted radiopharmaceutical therapy enhances CAR T-cell efficacy in pre-clinical models of neuroblastoma, Constanza Rodriguez, US Distinct subpopulations of cancer-associated fibroblasts (CAFs) drive neuroblastoma (NB) progression and drug resistance, Kevin Louault, US | Parallel Session 9: All Things MYCN (Basic) <i>Chairs: Carol Thiele, Adam Wolpaw</i> MYCN amplification shapes heterogeneity and cellular state dynamics in neuroblastoma, Stefano Di Giulio, US Heterogeneous oncogene dosage driven by extrachromosomal DNA determines neuroblastoma response to therapy, Giulia Montuori, Italy An integrated approach to discover and target oncogenic N-myc complexes, Bo Qiu, US The USP11/USP7/TCEAL1 complex stabilizes RNAPII during early transcription to sustain oncogenic gene expression, Gabriele Büchel, Germany The immunologic impact of MYCN downregulation in neuroblastoma cells, Kyabeth M. Torres Rodriguez, US | Parallel Session 10: Polyamines and Other Targets (Transl) <i>Chairs: Michael Hogarty, Annie Ryan</i> Systemic arginine deprivation with standard-of-care chemotherapy effectively treats high-risk neuroblastoma models, Kimberley M. Hanssen, Australia RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity, Jun Yang, US Pre-clinical development of novel AURKA degrading PROTACs for in vivo use, Muhammad Rishfi, Belgium The polyamine transporter ATP13A3 mediates resistance to DFMO in neuroblastoma cells and can be inhibited by AMXT 1501, Klaartje Somers, Australia Novel drug combinations exploit metabolic vulnerabilities in neuroblastoma, Conny Tümmler, Sweden |
| 16:40 - 18:10 | Poster Session Group B | | |
| 18:10 - 19:40 | Young Investigator Reception | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)
May 25 - 28, 2025
SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|-----------------------|--|---|--|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| Tuesday, May 27, 2025 | | | |
| Time Slot | Hall A (Potomac Room 1) | Hall B (Potomac Room 2) | Hall C (Meeting Room 16) |
| 08:00 - 08:45 | Education Session 2: Developmental Biology Isabella Janoueix-Lerosey & Laura Pahlberg | | Y-mAbs Therapeutics Sponsored Symposium |
| 08:45 - 09:00 | Comfort Break | | |
| 09:00 - 09:30 | Life Time Achievement Awards and INRG 20-Year Anniversary | | |
| 09:30 - 10:30 | Plenary Session 5: Plasticity and Evolution <i>Chairs: Rogier Versteeg, Rani George</i> Transcriptional diversity and cellular plasticity in neuroblastoma, Nora Fresmann, Germany Phenotypic plasticity is a heritable trait and drives adaptive evolution in neuroblastoma, Cecilia Roux, UK Unveiling the role of MYCN and ALK oncogenes in the early stages of neuroblastoma development using genetically engineered mouse models, Nour El Houda Djerir, France Spatial proteomics and single-cell RNA sequencing reveal subtype-specific immune interactions in neuroblastoma, Joseph S. Toker, US | | |
| 10:30 - 11:15 | Keynote Lecture 3 <i>Chair: William Weiss</i> Molecular and cellular mechanisms of SCLC progression and therapy response Julien Sage, US | | |
| 11:15 - 12:15 | Coffee Break & Poster Viewing Group C | | |
| 12:15 - 13:05 | Parallel Session 11: Plasticity and Heterogeneity (Basic) <i>Chairs: Isabelle Janoueix-Lerosey, Adam Durbin</i> Neuroblastoma PDX tumors include MES-type tumor cells, Ekaterina Skorova, Germany Generation of an In Vivo lineage tracing model of neuroblastoma to reveal mechanisms of therapy resistance, Ellen M. Westerhout, Netherlands Lineage-specific transcription factor screen identifies TFs that regulate neuroblastoma plasticity and drug resistance, Xingyu Liu, US CACNA2D3: A key regulator of phenotypic transdifferentiation in neuroblastoma by executing its function at RNA and protein level, Bharat Prajapati, Sweden A genome-derived non-coding cell state reporter permits targeting of cellular heterogeneity and reprogramming of chemoresistance, Noha AM Shendy, US | Parallel Session 12: More Mouse Models (Transl) <i>Chairs: John Maris, Kaat Durinck</i> A human stem cell model of neuroblastoma reveals candidate drivers of tumorigenesis on chromosome 17q, Wanqi Fang, US A humanized In Vivo model for neuroblastoma bone metastasis, Aleksandra Adamska, Sweden Generation of neural crest-derived neuroblastoma models to investigate MYCN vulnerabilities, Federica Lorenzi, UK Conditional c-MYC activation in catecholaminergic cells drives distinct tumors: neuroblastoma vs somatostatinoma, Jun Yang, US A tractable immunocompetent neuroblastoma murine model for immunoncology (IO) preclinical studies, Timothy T. Spear, US | Parallel Session 13: Targeted Imaging and Therapy (Clin) <i>Chairs: Steven DuBois, Shampavi Sriharan</i> Genomic and Transcriptomic Profiles Following 131I-MIBG Therapy on a Phase III Clinical Trial for High-Risk Neuroblastoma, Kevin L. Ying, US The impact of mIBG therapy in first-line treatment of patients with high-risk metastatic neuroblastoma: results of the GPOH study NB2004-HR, Thorsten Simon, Germany Initial toxicity and response data from MINIVAN, a Phase 1 trial of 131-I mIBG, Nivolumab and Dinutuximab Beta in relapsed/refractory neuroblastoma, Juliet C Gray, UK 225Ac alpha particle pre-targeted radioimmunotherapy (PRIT) with wide therapeutic window against neuroblastoma, Karina Leung, US 18F-meta-fluorobenzylguanidine (mFBG) PET Imaging in High-Risk Neuroblastoma Patients, Shakeel Modak, US |
| | Free Afternoon Activities | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)

May 25 - 28, 2025

SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|-------------------|---------------------|--------------------|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 19:30 - 00:00 | Gala Dinner | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)
May 25 - 28, 2025
SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|--------|-------------------|---------------------|--------------------|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |

| Wednesday, May 28, 2025 | | | |
|-------------------------|---|-------------------------|--------------------------|
| Time Slot | Hall A (Potomac Room 1) | Hall B (Potomac Room 2) | Hall C (Meeting Room 16) |
| 08:00 - 08:45 | Education Session 3: Immunology Paul Sondel & John Anderson | | |
| 08:45 - 09:00 | Comfort Break | | |
| 09:00 - 10:00 | Plenary Session 6: Of Mice and Models <i>Chairs: Jan Molenaar, Jamie Fletcher</i> Single cell analysis of murine neuroblastomas reveals developmental paths defined by telomerase activity and time, Lisa Werr, Germany Somatic focally amplified super-enhancers as novel oncogenic driver in neuroblastoma, Vincenzo Aievola, Italy KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma, Nina Weichert Leahey, US Exploiting the 17q gain/TRIM37 overexpression with the PLK4 inhibitor RP-1664 shows potent efficacy in preclinical high-risk neuroblastoma models, Minu Samanta, US | | |
| 10:00 - 10:15 | Rapid Fire Session 3 <i>Chair: Margaret Macy</i> Investigating the functional significance NB risk locus 6p22.3: Role of ATXN1-AS1 and NB specific super enhancer in NB development and progression, Kamali Nagarajan, Sweden Unmasking oncogenic drivers in neuroblastoma through integrative analysis and functional validation, Ryan Borchert, US A new core regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players of neuroblastoma plasticity, Cécile Thirant, France Evaluation of indocyanine green-labeled dinutuximab as a novel in vivo molecular imaging agent for neuroblastoma: an orthotopic murine model, William G Lee, US Long-term outcomes of patients with relapsed/refractory neuroblastoma treated on ANBL1221: A report from the Children's Oncology Group, Elizabeth Sokol, US Enhanced Recovery after Surgery (ERAS) improves length of stay and complications after resection of abdominal neuroblastoma, Sara A Mansfield, US FDG and FDOPA PET scans at diagnosis predict tumor behavior and gross total resection in neuroblastoma, Yen Lin Liu, Taiwan Characterization of the functional impact of G4 ligands on telomere maintenance mechanisms in high-risk neuroblastoma, Anna Borovkov, France BMP signaling determines neuroblastoma cell fate and sensitivity to retinoic acid, Min Pan, US Characterizing a panel of neuroblastoma patient-derived xenografts for response to induction and salvage chemotherapy, Min Hee Kang, US | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)

May 25 - 28, 2025

SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|---|--|---|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 10:15 - 11:15 | Plenary Session 7: Mostly Immunotherapy <i>Chairs: Juliet Gray, Daniel Morgenstern</i> Addition of eflornithine to chemoimmunotherapy does not improve response rate in relapsed/refractory neuroblastoma: A children's oncology group report, Margaret E Macy, US Anti-CD40 monoclonal antibody improves the efficacy of a current anti-GD2 chemo-immunotherapy regimen in a mouse neuroblastoma model, Alexander L Rakhmilevich, US IMiD drug regulation of CAR-T cell function and tumour environment modulation through ITAG2, a novel switch mechanism mediated by protein degradation, John Anderson, UK The super-enhancer driven nicotinic acetylcholine $\alpha 3\beta 4$ receptor complex as an immunotherapeutic target in high-risk neuroblastoma, Patrick Mark Schürch, US | | |
| 11:15 - 11:45 | Coffee Break | | |
| 11:45 - 12:35 | Parallel Session 14: Molecular Targeting Revisited (Transl) <i>Chairs: Louis Chesler, Alvin Kamilli</i> MYCN/Aurora-A complexes resolve transcription-replication conflicts by phosphorylating the T-loop of CDK12, Mareike Müller, Germany CDK9 Inhibition Suppresses MYCN-Driven Neuroblastoma and Enhances Immune Modulation, Evon Poon, UK The glycogen synthase kinase-3 β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model, Jayne Murray, Australia Arginine depletion via dietary or pharmacologic means potentially synergizes with high-dose DFMO to reprogram translation and regress neuroblastoma, Michael D. Hogarty, US Apatinib in Combination with Irinotecan and Temozolomide for Refractory/ Relapsed Neuroblastoma (APTN-01): A Multicenter, Single-Arm, Phase 1/2 Trial, Juan Wang, China | Parallel Session 15: Consequences of Therapy (Clin) <i>Chairs: Xiaojun Yuan, Molly Taylor</i> Ototoxicity prevalence in contemporary high-risk neuroblastoma therapy: A report from the Children's Oncology Group (COG) study ANBL1531, Mallory R. Taylor, US High risk neuroblastoma and second neoplasms: preliminary results of the SIOPEN HR-NBL1 study, Vassilios Papadakis, Greece Late effects in high-risk neuroblastoma survivors who received MIBG therapy, Perna Kumar, US Neonatal neuroblastoma with spinal canal involvement: a report from the SIOPEN Prospective Study Registry (NB-SCI), Maja Beck Popovic, Switzerland Two-year motor outcomes in children with neuroblastoma and spinal canal invasion: a report from the SIOPEN Prospective Study Registry (NB-SCI), Toby Trahair, Australia | Parallel Session 16: Epigenetics and Chromatin Targeting (Basic) <i>Chairs: Frank Westermann, Nina Weichert-Leahey</i> H3K27me3-mediated epigenetic repression regulates neuroblastoma development and contributes to biological heterogeneity, Charlotte Butterworth, France Combined PRC2 and Menin inhibition induces neuronal differentiation and GD2 expression through activation of bivalent chromatin domains, Nathaniel Mabe, US Inhibiting m6A reader proteins suppresses neuroblastoma growth and remodels the tumor microenvironment, Peng Xia, US CHAF1A reprograms oncogenic transcriptional networks to block neuroblastoma differentiation and promote oncogenesis, Vrajesh Karkhanis, US Targeting the interplay between replication stress (RS) induced DNA damage response (DDR) and epigenetics in children with high-risk neuroblastoma, Hannah E Hartley, Australia |
| 12:35 - 14:05 | Lunch Break & Poster Session Group C | | |

Advances in Neuroblastoma Research Meeting (ANR 2025)
May 25 - 28, 2025
SCIENTIFIC PROGRAM



| Legend | Keynote Lecture | Plenary Sessions | Education Sessions |
|---------------|--|--|--------------------|
| | Parallel Sessions | Rapid Fire Sessions | Poster Sessions |
| | Other Sessions | Sponsored Symposia | Social Events |
| 14:05 - 14:55 | <p>Parallel Session 17: All Things ALK (Transl) <i>Chairs: Yael Mosse, Sarah Cohen-Gogo</i></p> <p>Establishment of neuroblastoma treatment screening platform in multi-bio-models and multi-omics, Rui Dong, China Targeting the Anaplastic Lymphoma Kinase (ALK) Oncoprotein with Novel Immunotherapeutic Platforms in Neuroblastoma and ALK-Expressing Malignancies, Alberto D Guerra, US Targeting ALK in relapsed high-risk neuroblastoma: Real-world insights from the SACHA-France study, Pablo Berlanga, France ALK/ATR combination inhibition is effective in neuroblastoma mouse tumors driven by MYCN, Ruth Palmer, Sweden In-vitro and in-vivo analyses of resistance mechanisms to treatment combinations with ALK inhibitors in neuroblastoma, Angela Bellini, France</p> | <p>Parallel Session 18: Assorted Clinical Trials (Clin) <i>Chairs: Deborah Tweddle, Aditi VEDI</i></p> <p>Changes in outcome in patients with neuroblastoma over a 36-year time period: A report from the International Neuroblastoma Risk Group (INRG) project, Boris Decarolis, Germany Comparison of the prognostic impact of molecular risk factors in neuroblastoma, Carolina Rosswog, Germany Induction Regimens in High-Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities, Samantha Martin, US Arsenic trioxide combined with modified N7 induction regimen for high-risk neuroblastoma: a prospective, multicenter, single-arm, clinical study, Xiaomin Peng, China Sites of progressive disease in patients with high-risk neuroblastoma treated on new approaches to neuroblastoma Therapy (NANT) Trials, Araz Marachelian, US</p> | |
| 14:55 - 15:25 | Coffee Break | | |
| 15:25 - 16:10 | <p>Keynote Lecture 4 <i>Chair: Yael P Mosse</i></p> <p>How PROTAC degraders work: Molecular recognition and design principles Alessio Ciulli, UK</p> | | |
| 16:10 - 16:35 | Scientific Awards ANR 2025 | | |
| 16:35 - 17:00 | Closing Ceremony | | |